With Positive Boceprevir Data In Hand, Merck Prepares NDA Submission
This article was originally published in The Pink Sheet Daily
Executive Summary
Two Phase III trials evaluating the protease inhibitor in HCV met their primary endpoints but the real test is how boceprevir stacks up to Vertex's telaprevir.